On Wednesday and Thursday, the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee discussed.
On Wednesday and Thursday, the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee discussed the appropriate indicated population for testosterone replacement therapy (TRT) and the potential for adverse cardiovascular outcomes associated with this use.
There is little evidence that testosterone replacement therapy effectively treats normally declining levels of the hormone in aging American males, a U.S. Food and Drug Administration advisory panel said Wednesday.
The combined panel voted an overwhelmingly, 20-1, to tighten use of the popular drugs and require drug makers to conduct tests assessing the drugs’ risk of heart attack and stroke. The materials from this meeting can be found HERE.
On Thursday, the committees discussed new drug application (NDA) 206089, (oral testosterone undecanoate tablets), submitted by Clarus Therapeutics, for the proposed indication of testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
The panel pointed out there’s no clear scientific evidence showing testosterone replacement can reverse some of the effects of aging, and that there is growing evidence indicating that most men who are receiving testosterone replacement therapy do not actually need it. Only about half of the men now taking testosterone therapy have been diagnosed with hypogonadism (the specific medical diagnosis for testosterone deficiency) as found in an FDA analysis. Furthermore, 25% of men started testosterone therapy without lab testing to confirm that they had low levels of testosterone.
In an 18-3 vote, the panel voted that the overall risk-benefit profile of an oral formulation of testosterone undecanoate did not support approval at this time, citing issues with the pivotal trial, safety, and wide dietary-dependent variations in absorption.
The main results discussed in this meeting where from two phase III pharmacokinetic studies in hypogonadal adult men, whose mean age was about 55 years, with a total serum testosterone of 300 ng/dL or less. For approval of TRT products, the FDA requires a pharmacokinetic study.
A. Michael Lincoff, vice chairman of cardiovascular medicine at the Cleveland Clinic, said some members of the committee were concerned that an oral testosterone product “might tend to be used more off-label”—that is, for lifestyle enhancements such as increased sex drive and energy instead of medical reasons.
The FDA is not obligated to follow the advice of its advisory committees; however, it normally does so. The materials from this meeting can be found HERE.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us